A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
Active, not recruiting · Phase 2 · NCT05557591
Conditions: Advanced Non-Small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $294,151
- U.S. investigators named
- 11
- Sites paid
- 10
- Planned or actual enrollment
- 51
About the trial
- Sponsor
- Regeneron Pharmaceuticals (with BioNTech SE)
- Tested
- BNT116 (drug), Cemiplimab (drug)
- Dates
- Started 2023-04-21; completion 2028-05-16
- Results posted
- Not yet
This study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a "study drug", and together be called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aims of this study are to see how safe and tolerable BNT116 is in combination with cemiplimab and to see how effective BNT116 in combination with cemiplimab is compared to cemiplimab by itself at treating cancer. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drugs * How much study drug is in the blood at different times * Whether t…
From ClinicalTrials.gov, last updated 2026-05-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $294,151 in research payments for this study in 2025 (90 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Arati R. Chand, M.D. Hematology & Oncology · Los Angeles, CA
- Edward B. Garon, MD Hematology & Oncology · Los Angeles, CA
- Omkar S. Marathe, MD Hematology & Oncology · Lakewood, CA
- John T. Hamm, M.D. Medical Oncology · Louisville, KY
- Justin P. Favaro, MD Hematology & Oncology · Charlotte, NC
- Charles S. Kuzma, M.D. Hematology & Oncology · Pinehurst, NC
- Sardar Z. Imam, M.D. Hematology & Oncology · Farmington, NM
- Mark M. Awad, MD, PHD Medical Oncology · New York, NY
- Ashish Saxena, MD, PHD Hematology & Oncology · Flushing, NY
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
- Andrea L. Veatch, MD Hematology & Oncology · Puyallup, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Weill Medical College of Cornell University $134,894
- Virginia Cancer Specialists PC $62,959
- Firsthealth of the Carolinas Inc $30,776
- Ronald Reagan UCLA Medical Center, CA $26,262
- Norton Healthcare Inc $12,930
- Northwest Medical Specialties PLLC $11,092
- Dana Farber Mass General Brigham Cancer Care Inc $6,500
- Djl Clinical Research $3,500
- Toi Clinical Research $2,847
- San Juan Oncology Associates $2,391
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.